Is PFE a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

25,893 people get PFE articles and Market Currents by email alert.

Get email alerts on PFE »

FOCUS | PRO | RELATED | TRANSCRIPTS | NEWS & PR

Pfizer: Renal Cancer Treatment Sutent Sales Forecast
Pharma Reports • Mon, Jun 17
Pfizer For Zoetis: The Exchange, Market Mechanics & Analysis
Brad Ginesin • Sat, Jun 15 • 43 Comments
These 2 Healthcare Stocks Could Win Big With FDA's New 'Breakthrough' Status
StreetAuthority • Fri, Jun 14 • 4 Comments
Pfizer Is An Attractive Buy For Medium To Long-Term Investors
Investment Analytics • Wed, Jun 5 • 12 Comments
Pfizer: Get Ready To Load Up On Shares
Stock Gamer • Mon, Jun 3 • 16 Comments
Scrappy Upstarts Aiming For Pfizer's Xalkori Market
Cory Renauer • Mon, Jun 3 • 2 Comments
Why I'm Tendering My Shares Of Pfizer In Exchange For Zoetis
DG Ruralist • Fri, May 31 • 112 Comments
Pfizer Will Reward Shareholders With Zoetis Spin-Off
Chris Katje • Sat, May 25 • 52 Comments
Pfizer Has Potential To Grow Despite Decreasing Sales
Alpha Hunter • Fri, May 24 • 2 Comments
Pfizer's Direct-To-Consumer Campaigns: A Model For The Future?
Peter Geschek • Mon, May 13 • 2 Comments
An Update On Pfizer's Recently Approved Drugs
Jon Crowley • Tue, May 7 • 8 Comments
Pssstt! Pfizer Is Not Executing And Is Overvalued
Deep Dives • Tue, Apr 30 • 11 Comments
Whisper Number Impact: Earnings Preview For Pfizer
WhisperNumber • Mon, Apr 29 • 1 Comment
Enbrel's Asian Biosimilar Competitors
Peter Geschek • Fri, Apr 26 • 1 Comment
Can Pfizer Keep Up The Positive Momentum?
WM Analyst • Thu, Apr 18 • 4 Comments
Pfizer: Why You Should Be Cautious Now
Stock Gamer • Mon, Apr 15 • 6 Comments
Pfizer's New Breast Cancer Drug Could Be A Game Changer
StockBaller • Mon, Apr 15 • 4 Comments
Reasons For A Bullish Stance On Pfizer
StockRiters • Thu, Apr 11 • 2 Comments
FDA Designation May Accelerate Palbociclib Timeline But Not Increase Approval Probability
Deep Dives • Thu, Apr 11 • 3 Comments
Where Is Pfizer Heading With The Patent Cliff?
Emerging Equities • Tue, Apr 9 • 4 Comments

To learn more about Seeking Alpha Pro, click here.

Amgen In Focus
XY Trader • Wed, Jun 19 • 5 Comments
Zoetis Exchange Offer Update
Pine Research & Trading • Tue, Jun 18 • 13 Comments
CryoPort's Game-Changer In Frozen Biological Shipping
Brian Marckx • Tue, Jun 18 • 2 Comments
10 Top Dow Dogs Chase 9.5% To 16.4% Net Gains For June
Fredrik Arnold • Tue, Jun 18 • 3 Comments
Successor To Humira? AbbVie And Galapagos Work On It
Peter Geschek • Mon, Jun 17 • 1 Comment
Can Cempra Beat The Superbugs?
C.R. Jackson • Mon, Jun 17 • 1 Comment
Cramer's Mad Money - 9 Things To Watch In The Week Ahead (6/14/13)
SA Editor Miriam Metzinger • Sun, Jun 16 • 2 Comments
The Biggest Companies That Don't Pay Dividends - But May Be About To
StreetAuthority • Fri, Jun 14
Penny-Wise, Pound-Foolish Stem Cell Stocks
Emerging Equities • Fri, Jun 14 • 6 Comments
Pharma Majors: 2 To Buy, 1 To Avoid And 1 To Sell
The Ethical Investor • Fri, Jun 14 • 3 Comments
2 Healthcare Companies With Recent Intensive Insider Selling
Markus Aarnio • Thu, Jun 13 • 2 Comments
Time To Change Global Asset Allocation Strategy
BubbleBustInvesting • Wed, Jun 12 • 5 Comments
Portfolio Management - 10 Tips For Better Results
Rob_Stein • Wed, Jun 12 • 13 Comments
When It Comes To Biotech, Diversity Is Key
Mike Perinotti • Wed, Jun 12 • 5 Comments
Warning: The Rebound May Be Over For Big Pharma
StreetAuthority • Tue, Jun 11
AstraZeneca - Conducting Major Acquisitions
Investment Analytics • Tue, Jun 11
Sell Zoetis Into Supply
Pine Research & Trading • Mon, Jun 10 • 28 Comments
Interest Rates Up Round 1 - Sorting Through The Data
Daniel R Moore • Fri, Jun 7 • 5 Comments
What's Next For The Market: Buy Pfizer And US Airways, Sell Verifone
The Oxen Group • Fri, Jun 7 • 1 Comment
Old-School Pharma/Biotech Dividend Paying Comparison
Abba's Aces • Thu, Jun 6

Pfizer's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Tue, Apr 30
Pfizer's CEO Presents at Annual Shareholder Meeting Conference (Transcript)
Fri, Apr 26 • 5 Comments
Pfizer's CEO Discusses Q4 2012 Results - Earnings Call Transcript
Tue, Jan 29
Pfizer's CEO Discusses Q3 2012 Results - Earnings Call Transcript
Thu, Nov 1, 2012 • 1 Comment
Pfizer's CEO Discusses Q2 2012 Results - Earnings Call Transcript
Tue, Jul 31, 2012 • 2 Comments
Pfizer's CEO Discusses Q1 2012 Results - Earnings Call Transcript
Tue, May 1, 2012
Pfizer's CEO Hosts 2012 Annual Meeting (Transcript)
Thu, Apr 26, 2012 • 2 Comments
Pfizer's CEO Discusses Q4 2011 Results - Earnings Call Transcript
Tue, Jan 31, 2012 • 1 Comment
Pfizer's CEO Discusses Q3 2011 Results - Earnings Call Transcript
Tue, Nov 1, 2011
Pfizer's CEO Discusses Q2 2011 Results - Earnings Call Transcript
Tue, Aug 2, 2011
Pfizer's CEO Discusses Q1 2011 Results - Earnings Call Transcript
Tue, May 3, 2011 • 1 Comment
Pfizer's CEO Discusses Q4 2010 Results - Earnings Call Transcript
Tue, Feb 1, 2011 • 1 Comment
Pfizer CEO Discusses Q3 2010 Results - Earnings Call Transcript
Tue, Nov 2, 2010
Pfizer Q2 2010 Earnings Call Transcript
Tue, Aug 3, 2010
Pfizer Q1 2010 Earnings Call Transcript
Tue, May 4, 2010
Pfizer Inc. Q4 2009 Earnings Call Transcript
Wed, Feb 3, 2010
Pfizer, Inc. Q3 2009 Earnings Call Transcript
Tue, Oct 20, 2009
Pfizer Inc. Q2 2009 Earnings Call Transcript
Wed, Jul 22, 2009
Pfizer Q1 2009 Earnings Call Transcript
Tue, Apr 28, 2009
Pfizer Q4 2008 Earnings and Conference Call Transcript
Wed, Jan 28, 2009

CORRECTING and REPLACING Pfizer Announces Final Exchange Ratio of 0.9898 for Zoetis Exchange Offer and Automatic Extension of Offer to Midnight on Friday, June 21, 2013

Business Wire (Wed, 4:28PM)
Swanky Corporate Events Make Post-Recession Comeback

at Fox Business (Thu, 11:00PM)
Dow Closes Below 15000, Posts First 3-Day Losing Streak This Year

at CNBC.com (Jun 12, 2013)
Movers & Shakers: Wednesday’s movers: H-P up as CEO touts turnaround

at MarketWatch.com (Jun 12, 2013)
Pfizer Wins $2.15B Patent Suit with Teva, Sun Pharma

at Fox Business (Jun 12, 2013)
Pfizer Wins in $2.15 Billion Patent Infringement Case

at CNBC.com (Jun 12, 2013)
Pfizer Obtains $2.15 Billion Settlement from Teva and Sun for Infringement of Protonix® Patent

Business Wire (Jun 12, 2013)
Stock Futures Rebound from Selloff

at Fox Business (Jun 12, 2013)
Wall Street's Comeback Rally Loses Steam

at Fox Business (Jun 12, 2013)
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Business Wire (Jun 6, 2013)
Drug companies look to profit from DSM-5

at MarketWatch.com (Jun 5, 2013)
Americans Believe Their Communities Are Ill-Prepared For Aging Population, New Survey Reveals; Survey Shows A Fear Of Getting Old Due To Health And Financial Concerns

Business Wire (Jun 5, 2013)
Lightning Round: Barnes & Noble, Pfizer & More

at CNBC.com (Jun 3, 2013)
Pfizer Prices $4.0 Billion Debt Offering

Business Wire (May 28, 2013)
Corporate America Cracks Piggy Bank for Okla. Victims

at Fox Business (May 23, 2013)
Stocks Tumble Nearly 1% on Fed Tapering Fears

at CNBC.com (May 22, 2013)
Stocks Rally as Bernanke Defends Aggressive Fed Easing

at Fox Business (May 22, 2013)
Pfizer Announces Plan for Split-Off of Zoetis

Business Wire (May 22, 2013)
Futures Tick Up; Fed News on Tap

at Fox Business (May 22, 2013)
Stocks Climb on Dovish Fed Comments; Bernanke Up Next

at CNBC.com (May 21, 2013)

PFE vs. ETF Alternatives

Company Description

Pfizer Inc. (which may be referred to as Pfizer, the Company, we, us or our) is a research-based, global biopharmaceutical company. We apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in... More

Sector: Healthcare

Industry: Drug Manufacturers - Major

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, June 19, 4:48 PM Pfizer (PFE) discloses the final exchange ratio for the exchange its common stock for shares of its Zoetis (ZTS) spinoff. For each share of PFE common tendered, the shareholder will receive 0.9898 shares of Zoetis common stock, subject to proration if the exchange offer is oversubscribed. Based on the final exchange ratio and full subscription, PFE will accept for exchange 405,117,195 shares of its common stock. Shares +0.6% AH. 1 Comment [Healthcare]
Monday, June 17, 4:27 PM Zoetis (ZTS +0.5%) says it's joining the S&P 500 index, after Pfizer (PFE) splits off its remaining 80% stake in the animal-medicine company. It will replace First Horizon (FHN), which is replacing QLogic (QLGC) in the S&P MidCap 400 index. 1 Comment [Healthcare]
Thursday, June 13, 8:15 AM Tobacco companies (MO, PM, LO, RAI, BTI, ITYBY.PK) think they have the answer to where to find revenue growth with the advent of electronic cigarettes across the world, even as regulators struggle with the concept of if "safer" products are tolerable enough to allow the devices to work as a gateway to reducing nicotine addiction. If the future of e-cigarettes is as bright as tobacco players make it out to be, Pfizer (PFE) and GlaxoSmithKline (GSK) could see demand for their own nicotine addiction products turn lower. Comment! [Consumer]
Wednesday, June 12, 8:39 AM More on Protonix settlement: Teva (TEVA -1.3%) will pay $1.6B of the $2.15B, half in 2013 and the rest by October 2014, while Sun will pay its $550M share this year. The settlement follows a legal battle of almost 10 years in which a jury found that Teva and Sun violated the patent by launching generic versions of Protonix prior to the expiry of its patent in 2011. The deal also comes after the start of a trial to determine damages. Pfizer (PFE) +0.8%. (PR) 4 Comments [Healthcare, Top Stories]
Wednesday, June 12, 7:56 AM Pfizer (PFE) and Takeda (TKPHF.PK) obtain a $2.15B settlement from Teva (TEVA) and India's Sun for breaching a patent of Pfizer's and Nycomed's (now part of Takeda) blockbuster acid reflux medicine Protonix. Pfizer will receive 64% of the money and Takeda the rest. (PR) Comment! [Breaking News, Healthcare, Top Stories]
Friday, June 7, 1:24 PM Jefferies is out with some price target revisions and color after conducting a "global pharma review." Rundown: Top U.S. pick Abbott Laboratories (ABT +1.9%) reiterated at Buy, PT lowered to $44 from $46; top global pick Novartis (NVS +0.3%) has "positive growth inflection potential" in FY14; AbbVie (ABBV +0.6%), Roche (RHHBY.OB +2.5%), and Sanofi (SNY +0.5%) offer "attractive entry points" but ABBV's PT is lowered to $51 from $54; Johnson & Johnson's (JNJ +0.2%) PT lowered to $91 from $97; Merck (MRK -0.3%) has its price target raised to $56 from $54 and Pfizer (PFE +1.3%) has its target lowered slightly to $32. (Previous: Jefferies SOTP analysis) 3 Comments [Healthcare, On the Move]
Thursday, June 6, 9:37 AM Western drugs for baldness are gaining ground in China from traditional herbal remedies and even more esoteric treatments such as snake gall bladders. The market is small but has surged 90% to 100.7M yuan ($16.4M) in five years, and it looks like it could grow much further: in one survey, 47% of respondents said they had sought help for their hair loss. Companies that could benefit include Merck (MRK), J&J (JNJ), Pfizer (PFE) and L'Oreal (LRLCF.PK). 2 Comments [Healthcare]
Wednesday, June 5, 2:47 PM A study in the European Heart Journal suggests Alzheimer's drugs such as Pfizer (PFE -0.6%) and Eisai's (ESALF.PK) Aricept, Novartis' (NVS -1.3%) Exelon, and Johnson & Johnson's (JNJ -0.4%) Razadyne may reduce the risk of heart attacks and death. 2 Comments [Healthcare]
Saturday, June 1, 11:26 PM Pfizer's (PFE) Xalkori (crizotinib) — approved in August of 2011 for the treatment of non-small cell lung cancer patients who are ALK-positive — shows promise in extending progression-free survival when compared with the chemotherapy drugs pemetrexed and docetaxel, data from a clinical trial shows. The drug had sales of $53M in Q1. (WSJ) Comment! [Healthcare]
Wednesday, May 29, 2:18 PM Pfizer (PFE -2%) says that UPM Pharmaceuticals, a Baltimore-based drug development and contract manufacturer, has acquired the 500K square-foot commercial manufacturing facility that PFE currently operates in Bristol, Tenn. The new facility gives UPM the capability to annually produce 3.5B tablets and 680M capsules. As part of the purchase, UPM will continue to manufacture PFE's current portfolio of products within the facility for two years. Comment! [Healthcare, On the Move]
Friday, May 24, 7:27 AM Pfizer's (PFE) price target is hiked a buck to $29 at MKM Partners as the earlier-than-expected Zoetis (ZTS) spinoff has the team cutting their 2013 EPS forecast to $2.17 from $2.23, but raising estimates from 2014-17. The company remains a Hold however, as it's trading just above what MKM considers fair-value. Comment! [Healthcare]
Wednesday, May 22, 11:07 AM AIG remains at the top Goldman's list of hedge fund hotels (the 50 stocks appearing most frequently among hedge fund top 10 holdings). Google (GOOG) retains its #2 position. Apple (APPL) - in the top spot for 3 years until February - remains at #3. Goldman notes the basket has outperformed the S&P a bit this year and the top 20 has done better by more than 1000 basis points. We smell an ETF offering. The rest of the top 20: C, GM, PCLN, VMED, NWSA, MSFT, HTZ, JPM, APC, PFE, QCOM, CHTR, HES, CBS, EBAY, DAL, EQIX. 4 Comments
Wednesday, May 22, 8:18 AM Pfizer (PFE) plans to spin off its remaining stake in Zoetis (ZTS) through a tax-free exchange offer in which Pfizer owners can exchange their Pfizer shares for stock in Zoetis owned by Pfizer (got that?). Pfizer has received a waiver of the 180-day lock-up from the book runners of the Zoetis IPO. PFE +2.1%, ZTS -1.2% premarket. (PR) 11 Comments [Healthcare, Breaking News, On the Move]
Monday, May 20, 5:23 PM Pfizer (PFE) says it's discontinuing Phase 3 studies on its investigational compound inotuzumab ozogamicin in combination with rituximab, a treatment for patients with non-Hodgkin lymphoma who are not candidates for intensive high-dose chemotherapy, after the study failed to meet its primary objective of improving overall survival. No new or unexpected safety issues were identified, and PFE says it's continuing to review the the drug for potential subset applications. Shares -0.3% AH. Comment! [Healthcare]
Friday, May 10, 8:12 AM Pain Therapeutics (PTIE) craters 45.5% in premarket trading after Pfizer (PFE) says it is "considering its options" on Remoxy and may not respond to the FDA's complete response letter anytime in the next two years. PTIE sub-licensed Remoxy's commercialization rights to PFE subsidiary King Pharma (I, II). Comment! [Healthcare, On the Move]
Friday, May 10, 7:46 AM Pfizer (PFE) updates Durect (DRRX) on Remoxy, saying that it's "considering its options", and that if it elects to continue development of Remoxy, "we would not expect to submit a response to the "complete response" letter before mid-2015." (PR) This is less positive than expected by SA author Jason Napodano; shares are -12.6% premarket. 1 Comment [Healthcare, On the Move, Breaking News]

m@ximus
$PFE on wait and see mode, but solid outlook remains intact.
17 hours ago
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Ypa Finance
$PFE is a part of our quantitative S&P500 Dividend Portfolio http://bit.ly/15ZIU78
Jun 13, 10:52 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

m@ximus
Today's $PFE patent win news helped to hold.
Jun 12, 3:58 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

DAG1996
interesting that dividend-paying "safety stocks" pundits say to sell are only ones holding their ground on dips: $CAG, $KR, $PFE, etc.
Jun 11, 11:44 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Joseph P. Porter
$PFE was giving me the willies for a while. Finally looks to be back on track. Will it see $30 again soon?
Jun 7, 1:14 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

m@ximus
adding partial long position to $PFE. solid prospect for coming '13 Qs
May 31, 3:25 PM
Reply (2)

• !Report Abuse
View all 2 replies
djamison: Hopefully I made a good decision on buying PFE today ??
Jun 3, 11:58 AM
• !Report Abuse
m@ximus: $PFE solid fundamentals supporting market pressure. Better partial orders so you can average price paid on the downside if price goes down.
Jun 5, 3:35 PM
• !Report Abuse
Add a reply...

140 characters

gap123
getting very hard to ignore $PFE at this level. metrics still showing weakness, but I am starting a position today.
May 31, 1:52 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

m@ximus
addin $PFE at discount. opp will not last 4 ever
May 29, 3:21 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Dividend Sheet
$JPM $PFE and $GE are the most recommended Dogs of the Dow Jones - http://stks.co/pEMN - 10 shares with 3.45% Average Yield
May 27, 5:38 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Dhierin Bechai
Some stocks that might make a positive SMA cross: $ARIA, $CFN, $FFIV, $AWAY, $MPC, $PFE.
May 24, 10:52 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

m@ximus
adding partial long position to $PFE. solid prospect for coming '13 Qs
May 31, 3:25 PM
Reply (2)

• !Report Abuse
View all 2 replies
djamison: Hopefully I made a good decision on buying PFE today ??
Jun 3, 11:58 AM
• !Report Abuse
m@ximus: $PFE solid fundamentals supporting market pressure. Better partial orders so you can average price paid on the downside if price goes down.
Jun 5, 3:35 PM
• !Report Abuse
Add a reply...

140 characters

DAG1996
$PFE looking to add to position on pipeline valuation if dips to $28.00.
May 23, 12:29 PM
Reply (1)

• !Report Abuse
View all 1 replies
DAG1996: went ahead and added at $28.10 ... probably too early but still keeps my average below $24 so that's okay
May 29, 3:26 PM
• !Report Abuse
Add a reply...

140 characters

Chines33
Top longs from this price $BP $HIG $GILD $DD $FDX $SODA $EOG $WFM $ADT $YUM $SWK $WY $LEN $LNKD $NFLX $HD $EBAY $PFE $KMP $IGT
May 13, 11:09 PM
Reply (7)

• !Report Abuse
View all 7 replies
Chines33: Yes typically. It all depends on situation. Price, company, news, overall market. Lot of variables.
May 14, 12:07 PM
• !Report Abuse
wheelz23: i was swing trading, but have been day trading...it seems like swing trading is less work, more money for the stocks i was trading...thanks
May 14, 12:46 PM
• !Report Abuse
Add a reply...

140 characters

Nefas
Stocks i am watching next week $ZAGG, $MNKD, $HLF, $BBRY, $NOK, $MUX, $NBG, $PTIE, $PFE, $MTG..any suggestions ideas on my watchlist?
May 11, 10:02 AM
Reply (4)

• !Report Abuse
View all 4 replies
Seacap: I'm going to jump all over BBRY past 16.60
May 13, 12:24 AM
• !Report Abuse
Bigisbetter: DDD
May 14, 12:35 PM
• !Report Abuse
Add a reply...

140 characters

Joseph P. Porter
$PFE making another run to go over $30.00. Maybe they'll manage to stay up there this time - or have they hit the ceiling?
May 13, 11:58 AM
Reply (3)

• !Report Abuse
View all 3 replies
Joseph P. Porter: If they were to get some bad news it might help bring the price down a little bit, but I think last week was their down week.
May 13, 12:52 PM
• !Report Abuse
DAG1996: True, last week was probably $PFE near-term bottom, but might depend more on market-wide movement ... finally feeling toppy short term.
May 13, 12:56 PM
• !Report Abuse
Add a reply...

140 characters

Gare17
If we don't hear from $ZLCS next Monday or Tuesday with Novartis renewal I think buyout rumors will start .. $NVS $MRK $PFE #Ions
Apr 26, 12:43 PM
Reply (1)

• !Report Abuse
View all 1 replies
Gare17: $ZLCS buyout or spinoff with $NVS for Chts technology
Apr 29, 4:17 PM
• !Report Abuse
Add a reply...

140 characters

Joseph P. Porter
The mixed week in earnings takes its toll today: $CUR, $DCIX, $KKR, $ONTY, $PFE and $RNO all down, even though many gave good news this week
Apr 26, 12:22 PM
Reply (5)

• !Report Abuse
View all 5 replies
neobliviscar: Ja mata. Let me frame it then. The stock is only up +10% this week. It was up +11%, except for that Charlie Sheen Violent Torpedo of Truth.
Apr 26, 1:34 PM
• !Report Abuse
Joseph P. Porter: P.S. I'm long DCIX.
Apr 26, 2:16 PM
• !Report Abuse
Add a reply...

140 characters

Joseph P. Porter
$PFE pfaithfully pfollows its tradition of offering its divs - $0.24 to be paid in June. Pfar out.
Apr 25, 2:32 PM
Reply (3)

• !Report Abuse
View all 3 replies
Joseph P. Porter: Absolutely pfabulous, in my book. Pfizer is to dividends what prunes are to BM's - regularity exemplified. $PFE is pfar and away the best
Apr 25, 9:53 PM
• !Report Abuse
Joseph P. Porter: company I have shares in. So pfar, more than 30% return, not counting divs. Pfortunately, I bought in over a year ago.
Apr 25, 9:55 PM
• !Report Abuse
Add a reply...

140 characters

The Hammer
$PFE breaking out multi-year highs. Lots of investors jumped ship early on this one. It is getting close to oversold. how far does this run?
Jan 9, 4:10 PM
Reply (6)

• !Report Abuse
View all 6 replies
The Hammer: Broke above $30 nice. however the pure pharma business model is riskier than the nvs or jnj model more preferred. Hope it runs fast
Apr 11, 9:57 AM
• !Report Abuse
The Hammer: will lighten up into a nice spike from here. reinvested every div over something like 7 years or so.
Apr 11, 9:58 AM
• !Report Abuse
Add a reply...

140 characters

Chines33
$PFE ftw!!!!!!!!
Apr 10, 3:45 PM
Reply (4)

• !Report Abuse
View all 4 replies
Chines33: Only 1 of 2 longs I've had for over a year. Largest position still.
Apr 10, 3:56 PM
• !Report Abuse
bd4uandu: Glad you clarified that in other circles it has other meanings.
Apr 10, 3:58 PM
• !Report Abuse
Add a reply...

140 characters

m@ximus
sold $SPY and got into $PFE long. is this an ongoing fractional Correction?
Apr 5, 2:44 PM
Reply (2)

• !Report Abuse
View all 2 replies
Joseph P. Porter: From Bloomberg - it sounds as if the "correction" could become a Q2-long phenomenon, depending on earnings. They will have to pry $PFE out
Apr 8, 5:51 PM
• !Report Abuse
Joseph P. Porter: of my cold, dead hands. Q2 tends to be a bit iffy, anyway. Much pessimism out there right now because of soft job #'s and Europe.
Apr 8, 5:54 PM
• !Report Abuse
Add a reply...

140 characters

Chines33
Favorite longs remain $MRK $PFE $HRB willing to add. Other longs I'm looking add starting/re adding:
Apr 3, 8:56 PM
Reply (4)

• !Report Abuse
View all 4 replies
Noreika: Glad to see you back Chines
Apr 4, 7:27 AM
• !Report Abuse
Chines33: Thanks.
Apr 4, 4:05 PM
• !Report Abuse
Add a reply...

140 characters

DAG1996
GE, PFE, CSCO, INTC, ORCL, MSFT, AKS, CHK & WTR - buy now or wait til after earnings? all opinions welcomed
1/17/12
Reply (28)

• !Report Abuse
View all 28 replies
Jim Warlick: I've seen a large amount of research on ORCL and largely expect them to achieve 10-15% earnings this year. Watch developing cloud tech. BUY
Feb 27, 2:55 PM
• !Report Abuse
madav1138: AKS 1.15 eps by 2015
Mar 16, 6:38 AM
• !Report Abuse
Add a reply...

140 characters

Joseph P. Porter
$DCIX, $FSC, $AMD, $ONTY, $PFE, $$RNO, $TCAP all up big time. $ONTY up 7.53% - about time people took advantage of big discount.
Feb 27, 3:01 PM
Reply (4)

• !Report Abuse
View all 4 replies
djamison: I know !!! Just when I was thinking things were are looking good !!
Mar 1, 9:03 AM
• !Report Abuse
Joseph P. Porter: They're good - it's just best to not pay attention to their stock price. $PFE is the best performing stock I have had long term, so I cope.
Mar 1, 11:10 AM
• !Report Abuse
Add a reply...

140 characters

Michael Bryant
"Zoetis's 17 percent sales growth in 2011 outpaced all but Lilly's animal unit..." Wonder how big a stake Pfizer ($PFE) still has.
Feb 1, 11:39 AM
Reply (1)

• !Report Abuse
View all 1 replies
Deep Dives: I believe 82% of A-shares and 100% of B Shares.
Feb 6, 3:31 PM
• !Report Abuse
Add a reply...

140 characters

PFE Pfizer Inc.

PFE

Pfizer Inc.